Catalent Inc (CTLT)

113.00
-3.26(-2.80%)
After Hours
113.30
+0.30(+0.27%)
- Real-time Data
  • Volume:
    447,161
  • Bid/Ask:
    110.52/113.50
  • Day's Range:
    112.77 - 115.70
  • Type:Equity
  • ISIN:US1488061029
  • S/N:148806102

CTLT Overview

Prev. Close
116.26
Day's Range
112.77-115.7
Revenue
3.76B
Open
115.39
52 wk Range
79.65-127.68
EPS
2.96
Volume
447,161
Market Cap
19.25B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
907,691
P/E Ratio
39.29
Beta
1.42
1-Year Change
42.41%
Shares Outstanding
170,341,553
Next Earnings Date
Aug 30, 2021
What is your sentiment on Catalent Inc?
or
Market is currently closed. Voting is open during market hours.

Catalent Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellBuyStrong Buy
Technical IndicatorsBuyStrong SellStrong SellStrong BuyStrong Buy
SummaryNeutralStrong SellStrong SellStrong BuyStrong Buy

Catalent Inc Company Profile

Catalent Inc Company Profile

Employees
13900

Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Read More
  • moderna, regeneron, j&j
    0
    • solid growth company
      0
      • Market close 21 Jun appears like frying pan...
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.